Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies.
about
Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpuraComplement activation on platelets: implications for vascular inflammation and thrombosis.The role of platelets in antiphospholipid syndrome.Platelet activation and anti-phospholipid antibodies collaborate in the activation of the complement system on platelets in systemic lupus erythematosus.The intrinsic complement regulator decay-accelerating factor modulates the biological response to vascular injuryAssociation between aspirin therapy and the outcome in critically ill patients: a nested cohort studyEvasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancerClinicopathologic correlations of renal microthrombosis and inflammatory markers in proliferative lupus nephritis.Pathophysiological mechanisms in antiphospholipid syndromePlatelet mediated complement activationIdentification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O).Complement and non-complement activating functions of C1q: a prototypical innate immune molecule.Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals.New Insights on Platelets and Platelet-Derived Microparticles in Systemic Lupus Erythematosus.Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus--a possible link to venous thrombosis?Cell-bound complement activation products in SLE.Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.Complement activation, a threat to pregnancy.Platelet activation, adhesion, inflammation, and aggregation potential are altered in the presence of electronic cigarette extracts of variable nicotine concentrations.Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus.Migraineurs show a high prevalence of antiphospholipid antibodiesC3b-Independent Complement Activation in Ischemia/Reperfusion Mesenteric Tissue Injury in Autoimmune Prone (B6.MRL/lpr) Mice
P2860
Q33387105-84BE4250-C4FF-4D40-BD2F-1BC2246E830FQ33390662-C8601D59-7148-4152-84B8-8579C02BCFD0Q33439904-F5D63816-C045-4BFC-8978-59B1ACE2025DQ33748970-6D19E209-D584-41EE-9ADB-5E3182A87A13Q33990334-9DE0FD1A-131D-4184-83B8-2A4D8CB1D9ABQ35916354-1CAB6CC6-5469-4508-AC8B-D0DBE362FB49Q36090335-5C1F5271-F232-4F6D-9B3F-1319AEA9F7CCQ36246049-3DF5484A-8323-4CEC-B30B-3A68F2CC5B00Q36671159-304E2430-700E-4A76-B684-2AC54F22789BQ37088046-42F3A95B-7A19-4608-88FB-E68C89FA11C5Q37200463-7BBBB0A5-FD61-4912-8D1B-CD3884603806Q37859539-7A269BEF-9260-4E54-84DA-2F5225B1F5E9Q38718092-03B2256B-CCEC-4F95-A613-4E125E5D5061Q39440991-8A681E1A-6E03-462D-B46C-FF5A326C0D40Q43581917-E7AEA029-9067-45AD-AFA0-A1E5BA1F0932Q46275219-DA2DC182-DC93-449B-918E-0E9BCD9F34EFQ46459006-F7451A30-CFD4-47BD-AC08-674A1AB9FE52Q47998109-98A3D278-6A51-4DC6-B2EB-E8E633D6B90FQ48662976-837B9223-BE74-4B7F-BC01-ECE85BFF3A54Q51110153-D84FC975-880B-4071-869D-D5C6AD6B9611Q51724929-7741660A-3FE8-4894-859E-EE83F558043EQ57272263-DF2A5CFE-606A-4A81-8F4C-4252C4A06FE8Q58692186-CC96E4F6-E5DC-4D9D-A562-DEFF818111A2
P2860
Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Serum complement activation on ...... d antiphospholipid antibodies.
@en
Serum complement activation on ...... d antiphospholipid antibodies.
@nl
type
label
Serum complement activation on ...... d antiphospholipid antibodies.
@en
Serum complement activation on ...... d antiphospholipid antibodies.
@nl
prefLabel
Serum complement activation on ...... d antiphospholipid antibodies.
@en
Serum complement activation on ...... d antiphospholipid antibodies.
@nl
P2093
P2860
P356
P1433
P1476
Serum complement activation on ...... d antiphospholipid antibodies.
@en
P2093
B Ghebrehiwet
D R Alpert
E I B Peerschke
J E Salmon
R A S Roubey
P2860
P304
P356
10.1177/0961203308099974
P577
2009-05-01T00:00:00Z